Pacira BioSciences, Inc. (PCRX) — Fair Value Analysis
Base-case fair value (P50): $23.18 · Current price: $23.00 · Verdict: Fairly Valued
The Verdict on PCRX
PACIRA BIOSCIENCES INC (PCRX) is currently deemed Fairly Valued according to our Monte Carlo simulations. The current market price of $23.00 sits remarkably close to our median fair value (P50) estimate of $23.18. This indicates a marginal +0.8% potential, suggesting the market's present valuation largely aligns with our quantitative assessment of the company's intrinsic worth. For investors, this implies PCRX is trading near its equilibrium point, with significant immediate undervaluation or overvaluation not evident at $23.00.
How PCRX stacks up against peers
With an unrated quality tier, a direct, comprehensive comparison of PCRX's operational and financial health against its sector peers is not currently available in this specific dimension. Our fair value assessment for PCRX, however, is derived purely through a probabilistic quantitative methodology, independent of this qualitative health score. The close alignment between $23.00 and the $23.18 fair value suggests that, irrespective of an explicit quality rating, the market may already be reflecting most known fundamental information. Given the sector is listed as 'n/a', broader industry-specific trends are incorporated implicitly within the Monte Carlo's forward projections, rather than through direct peer quality comparisons.
What this means for investors
The Fairly Valued verdict and the minimal +0.8% from $23.00 to $23.18 imply that PCRX is trading efficiently against its median intrinsic value. While the P50 provides a central tendency, Monte Carlo simulations rigorously model thousands of potential future scenarios, encompassing both downside scenarios and more optimistic bull cases. Investors seeking a deeper understanding beyond this median fair value should recognize that the probabilistic "FairCurve" framework captures this entire spectrum of outcomes. Sign up for FairCurve to access the full bear/bull distribution and track PCRX's fair value as new financial fundamentals are released.
Frequently Asked Questions
Is PCRX overvalued or undervalued right now?
Based on our Monte Carlo simulations, PACIRA BIOSCIENCES INC (PCRX) is currently Fairly Valued. Its current price of $23.00 is very close to our median fair value estimate of $23.18.
What is the bear case and bull case for PCRX?
The full Monte Carlo distribution, including our bear (P10) and bull (P90) target prices, along with the probability of achieving upside, is available with a free FairCurve account. We do not provide specific dollar values here, but the simulation models a wide range of potential outcomes.
How does FairCurve calculate PCRX's fair value?
FairCurve calculates PCRX's fair value using a sophisticated Monte Carlo simulation that models thousands of forward scenarios based on various financial inputs. This probabilistic approach generates a range of potential fair values, with $23.18 representing the median.
How can I track PCRX's fair value as it changes?
You can add PCRX to a free FairCurve watchlist for daily fair-value updates. Our system also provides instant re-valuation of PCRX's fair value whenever new earnings reports or significant financial data are released.